Lunai Bioworks Inc. (NASDAQ:LNAI) has unveiled promising preliminary findings from its artificial intelligence-driven platform that aims to identify compounds interacting with acetylcholinesterase (AChE), a target notably affected by chemical agents like the nerve agent Sarin. This announcement was made on October 30, 2025, amid escalating global concerns regarding the potential use of chemical weapons.
“This research brings us closer to a future where proactive, AI-powered screening can detect and evaluate neurotoxic compounds before they become threats,” stated David Weinstein, CEO of Lunai Bioworks. The company envisions utilizing in vivo systems such as zebrafish, alongside predictive AI, to swiftly identify neurotoxic risks and assess potential countermeasures.
Lunai”s platform employs a combination of chemical feature analysis and machine learning classifiers, achieving a high accuracy rate of 0.94 AUROC (Area Under the Receiver Operating Characteristic curve) in distinguishing active AChE inhibitors from inactive substances. This research builds on models developed using the company”s internal neuroactive compound screening data, as well as publicly available datasets, focusing on identifying chemical signatures linked to AChE inhibition.
Through this innovative approach, Lunai has identified compounds with previously unrecognized potential neurotoxic activity that warrant further investigation and validation. The company”s commitment emphasizes a responsible application of AI technology aimed at enhancing defense and public health, especially in light of concerns surrounding the misuse of generative AI technologies.
The future steps for Lunai include integrating its behavioral zebrafish profiling platform, which will allow researchers to observe real-time physiological effects of the predicted inhibitors. This integration aims to prioritize candidate compounds for development as potential countermeasures. Zebrafish are recognized by the FDA as an effective model for toxicology and drug discovery due to their genetic relevance to humans and their scalability, which surpasses that of traditional rodent models.
Lunai”s platform harnesses these benefits by combining high-throughput behavioral assays in zebrafish with machine learning models trained to identify neurotoxic phenotypes. This methodology facilitates rapid and cost-effective screening of both suspected threat agents and potential countermeasures, significantly reducing the time required to identify viable candidates from months to mere days—an essential factor in urgent defense and public health scenarios.
To foster collaborative efforts, Lunai has created a customized dashboard that incorporates its predictive model, enabling partners to analyze their chemical structures and assess their potential neurotoxicity.
Lunai Bioworks Inc. is at the forefront of AI-driven drug discovery and biodefense, focusing on developing safe and responsible generative biology. By utilizing proprietary neurotoxicity datasets and advanced machine learning techniques, the company aims to redefine how artificial intelligence can accelerate therapeutic advancements while protecting society from emerging threats.
As a precautionary note, this press release contains “forward-looking statements” which reflect the management”s plans and expectations regarding future operations and market trends. Such statements are based on current assumptions and beliefs, which are subject to various risks and uncertainties.
For further inquiries, please contact: [email protected] or visit www.lunaibioworks.com.
